Pipeline

Ervaxx has identified proprietary Dark Antigens™ that map to solid tumor types and generate robust, antigen-specific T cell responses. We are leveraging these insights to advance a pipeline of off-the-shelf cancer vaccines and TCR-based immunotherapies for cancer.

Target Discovery
& Validation

Product
Candidate

GMP &
Toxicology

Proof of
Concept

Melanoma
NSCLC
Ovarian
Undisclosed : Partnered
Indication 1
Undisclosed : Partnered
Indication 2
TCR Programs